REN and type 2 diabetes mellitus: Renin–angiotensin system inhibitors, sodium–glucose co-transporter 2 inhibitors (SGLT2i), and finerenone provide both kidney protection and reduction of risk of CV events in patients with T2D and high CV risk or CKD.6–12 These therapies are an essential part of a foundation of optimal care as recommended by clinical practice guidelines for this population of people with T2D.13,14 Despite these evidence-based therapies, there is a clear unmet need for additional effective therapies in this patient population as a high residual risk is still present.